Saumen Chattopadhyay says Gilead Sciences will remain the leader in Hepatitis C treatment, and will maintain a strong leadership position. He notes that driving growth for the company remains to be its solid HIV product portfolio, but that forward P/E multiples have compressed over the last year. For this reason, Vertex Pharmaceuticals is his top pick in the biotech space, as it now is trading below the historical average. Tom White then looks at example trades in both Vertex Pharmaceuticals and Gilead Sciences.